NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME
Background. Carriership of CYP4F2*3 (rs2108622, Val433Met) allelic variant can affect antiplatelet effect of clopidogrel, thus changing efficacy and safety of its standard dose.Aim. To study the impact of carriership of at least one CYP4F2*3 allele on the risk of resistance to clopidogrel in patient...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2018-03-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/1617 |
| _version_ | 1826949648235888640 |
|---|---|
| author | K. B. Mirzaev O. D. Konova E. A. Grishina K. A. Ryzhikova Zh. A. Sozaeva D. A. Andreev M. Y. Gilyarov D. A. Sychev |
| author_facet | K. B. Mirzaev O. D. Konova E. A. Grishina K. A. Ryzhikova Zh. A. Sozaeva D. A. Andreev M. Y. Gilyarov D. A. Sychev |
| author_sort | K. B. Mirzaev |
| collection | DOAJ |
| description | Background. Carriership of CYP4F2*3 (rs2108622, Val433Met) allelic variant can affect antiplatelet effect of clopidogrel, thus changing efficacy and safety of its standard dose.Aim. To study the impact of carriership of at least one CYP4F2*3 allele on the risk of resistance to clopidogrel in patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI).Material and methods. The study enrolled 81 patients with ACS and PCI: 64 males and 17 females, mean age 63.9±10.9 years. CYP4F2 allelic variants were detected by the method of real-time polymerase chain reaction. Platelet functional activity was evaluated by a portative aggregometer – the VerifyNow P2Y12 assay.Results. Pharmacogenetic testing showed that 40 (49.4%) of ACS patients had normal genotype (CC), 38 (46.9%) patients were carriers of one associated with reduced drug metabolism allele (CT genotype), and 3 (3.7%) patients were homozygotes for T (TT genotype). Genotype and allele distribution was in the Hardy-Weinberg equilibrium (c2=2.79; p=0.095). There were no statistically significant differences in CYP4F2*3 allele frequency between patients that are resistant to clopidogrel (PRU>208) and in patients with a normal response to clopidogrel (PRU<208): 36.8% vs 54.8% (р=0.17). Average platelet reactivity units (PRU) and average platelet inhibition (%) in patients with and without T allelic variant of CYP4F2 also were not significantly different: 165.34±51.03 PRU vs 174.8±51.06 PRU (p=0.407), respectively, and 29.51±21.59% vs 27.72±18.35%, respectively (p=0.69).Conclusion. Carriership of CYP4F2*3 allelic variant does not affect antiplatelet effect of clopidogrel in ACS patients. Further research on larger samples is needed to determine the role of CYP4F2 polymorphisms in personalization of clopidogrel antiplatelet therapy. |
| first_indexed | 2024-03-08T14:02:10Z |
| format | Article |
| id | doaj.art-8466845adaf0447588e51de160d4be11 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2025-02-17T22:17:44Z |
| publishDate | 2018-03-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-8466845adaf0447588e51de160d4be112024-12-04T11:48:14ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532018-03-01141475210.20996/1819-6446-2018-14-1-47-521445NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMEK. B. Mirzaev0O. D. Konova1E. A. Grishina2K. A. Ryzhikova3Zh. A. Sozaeva4D. A. Andreev5M. Y. Gilyarov6D. A. Sychev7Russian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional Education Barrikadnaya ul. 2/1, Moscow, 123995Russian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional EducationRussian Medical Academy of Continuous Professional EducationI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityRussian Medical Academy of Continuous Professional EducationBackground. Carriership of CYP4F2*3 (rs2108622, Val433Met) allelic variant can affect antiplatelet effect of clopidogrel, thus changing efficacy and safety of its standard dose.Aim. To study the impact of carriership of at least one CYP4F2*3 allele on the risk of resistance to clopidogrel in patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI).Material and methods. The study enrolled 81 patients with ACS and PCI: 64 males and 17 females, mean age 63.9±10.9 years. CYP4F2 allelic variants were detected by the method of real-time polymerase chain reaction. Platelet functional activity was evaluated by a portative aggregometer – the VerifyNow P2Y12 assay.Results. Pharmacogenetic testing showed that 40 (49.4%) of ACS patients had normal genotype (CC), 38 (46.9%) patients were carriers of one associated with reduced drug metabolism allele (CT genotype), and 3 (3.7%) patients were homozygotes for T (TT genotype). Genotype and allele distribution was in the Hardy-Weinberg equilibrium (c2=2.79; p=0.095). There were no statistically significant differences in CYP4F2*3 allele frequency between patients that are resistant to clopidogrel (PRU>208) and in patients with a normal response to clopidogrel (PRU<208): 36.8% vs 54.8% (р=0.17). Average platelet reactivity units (PRU) and average platelet inhibition (%) in patients with and without T allelic variant of CYP4F2 also were not significantly different: 165.34±51.03 PRU vs 174.8±51.06 PRU (p=0.407), respectively, and 29.51±21.59% vs 27.72±18.35%, respectively (p=0.69).Conclusion. Carriership of CYP4F2*3 allelic variant does not affect antiplatelet effect of clopidogrel in ACS patients. Further research on larger samples is needed to determine the role of CYP4F2 polymorphisms in personalization of clopidogrel antiplatelet therapy.https://www.rpcardio.online/jour/article/view/1617cyp4f2acute coronary syndromepharmacogeneticsclopidorgelp2y12-receptor blockers. |
| spellingShingle | K. B. Mirzaev O. D. Konova E. A. Grishina K. A. Ryzhikova Zh. A. Sozaeva D. A. Andreev M. Y. Gilyarov D. A. Sychev NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME Рациональная фармакотерапия в кардиологии cyp4f2 acute coronary syndrome pharmacogenetics clopidorgel p2y12-receptor blockers. |
| title | NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME |
| title_full | NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME |
| title_fullStr | NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME |
| title_full_unstemmed | NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME |
| title_short | NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME |
| title_sort | nfluence of cyp4f2 3 on response to clopidogrel in patients with acute coronary syndrome |
| topic | cyp4f2 acute coronary syndrome pharmacogenetics clopidorgel p2y12-receptor blockers. |
| url | https://www.rpcardio.online/jour/article/view/1617 |
| work_keys_str_mv | AT kbmirzaev nfluenceofcyp4f23onresponsetoclopidogrelinpatientswithacutecoronarysyndrome AT odkonova nfluenceofcyp4f23onresponsetoclopidogrelinpatientswithacutecoronarysyndrome AT eagrishina nfluenceofcyp4f23onresponsetoclopidogrelinpatientswithacutecoronarysyndrome AT karyzhikova nfluenceofcyp4f23onresponsetoclopidogrelinpatientswithacutecoronarysyndrome AT zhasozaeva nfluenceofcyp4f23onresponsetoclopidogrelinpatientswithacutecoronarysyndrome AT daandreev nfluenceofcyp4f23onresponsetoclopidogrelinpatientswithacutecoronarysyndrome AT mygilyarov nfluenceofcyp4f23onresponsetoclopidogrelinpatientswithacutecoronarysyndrome AT dasychev nfluenceofcyp4f23onresponsetoclopidogrelinpatientswithacutecoronarysyndrome |